Related by context. All words. (Click for frequent words.) 82 Initiates Clinical Trial 82 Completes Patient Enrollment 82 Completes Enrollment 81 Presents Positive 80 Present Preclinical Data 80 Initiates Clinical 79 Phase 2b Clinical Trial 79 Presents Preclinical Data 78 Files IND 78 Receives Milestone Payment 78 Initiates Phase II 78 Begins Dosing 78 Drug Candidate 77 Initiates Enrollment 77 Announces Presentation 77 Meets Primary Endpoint 77 Clinical Trial Results 77 Initiates Phase III 77 Completes Dosing 76 Successfully Completes Phase 76 Initiates Dosing 76 Announces Initiation 76 Preclinical Data 76 FDA Clears 76 Phase 2b Trial 76 Collaborators Publish 76 Reports Preclinical Data 76 Commences Phase 76 Receives Orphan Drug Designation 75 Shows Promising 75 Demonstrates Positive 75 Immunomedics Announces 75 Lupus Drug 75 Presents Preclinical 75 Study Demonstrates 75 Submits Biologics License Application 75 Presents Positive Preclinical 75 Improves Survival 75 Submits NDA 75 Phase IIb Clinical Trial 75 Enrolls First 75 Drug Shows Promise 74 Therapeutic Competitors Companies 74 Initiates Phase 74 Phase 2a Trial 74 Licenses Novel 74 Oral Calcitonin 74 Cites Positive 74 Develop Novel 74 Significantly Improves 74 Anti Tumor Activity 74 Phase III Clinical Trial 74 Vaccine Adjuvant 74 Receives Orphan Drug 74 Announce License Agreement 74 Phase IIa Clinical Trial 74 Demonstrates Significant 74 Announce Initiation 74 Prolongs Survival 74 Drug Fails 74 RNAi Therapeutic 74 Reveals Positive 73 First Patient Enrolled 73 Researchers Identify 73 Improves Outcomes 73 Inc. Nasdaq OXGN 73 Earns Milestone Payment 73 FDA Okays 73 Patient Enrollment 73 Preclinical Study 73 Shows Promise Against 73 Reports Positive 73 Announces Publication 73 Shows Promise 73 pralatrexate injection folate analogue 73 Achieves Milestone 73 Pivotal Phase 73 Kinase Inhibitor 73 Anti Tumor 73 Test Detects 73 Submits IND 73 Novel Oral 73 Trial Evaluating 73 JAK2 Inhibitor 73 Monoclonal Antibody 73 Submits Response 73 Initiate Phase 73 Study Evaluating 73 Lung Cancer Drug 73 Identifies Potential 73 Nicotine Vaccine 72 Initiates Phase 2b 72 Phase IIb Trial 72 Systemic Delivery 72 Announce Merger Agreement 72 Receives FDA Clearance 72 Pivotal Phase III 72 Announces FDA Clearance 72 Patients Treated With 72 Therapeutic Antibody 72 FDA Approvals 72 Patent Covering 72 Pivotal Study 72 Announces Issuance 72 Epilepsy Drug 72 Granted Orphan Drug 72 Investigational Compound 72 Slow Progression 72 Gout Drug 72 Mouse Model 72 Antibody Drug Conjugate 72 Migraine Drug 72 Helps Predict 72 Receive Milestone Payment 72 Announces Successful Completion 72 Study Indicates 72 Biomarker Study 72 Announces Dosing 72 Pooled Analysis 72 Mouse Models 72 Announces Poster Presentations 72 Antitumor Activity 72 Small Molecule 71 Investigational Treatment 71 FDA Accepts 71 Phase III Trial 71 Novel Therapeutic 71 Combination REOLYSIN R 71 Pharmacyclics Announces 71 Prostate Cancer Vaccine 71 Receives Approvable Letter 71 RNAi Therapeutics 71 Prophylactic Treatment 71 Demonstrates Potential 71 Combination Treatment 71 Achieves Primary Endpoint 71 Cholesterol Lowering Drug 71 Q2 Loss Narrows 71 Tyrosine Kinase Inhibitor 71 Milestone Payment 71 Receives Patent 71 Demonstrated Significant 71 Antigen Specific 71 Lung Cancers 71 Tumor Targeting 71 Announces Positive 71 Proves Effective 71 Advanced Melanoma 71 Provides Update Regarding 71 Reduces Risk 71 IND Filing 71 Receives Fast Track 71 Study Showed 71 Demonstrates Potent 71 Initiate Phase III 71 Molecular Diagnostic Test 71 Scientists Identify 71 Gene Linked 71 Awarded Qualifying Therapeutic 71 Cancer Stem Cells 71 HCV Protease Inhibitor 71 Demonstrates Efficacy 71 Announce Collaboration Agreement 71 Biogen Genentech 71 Genes Linked 71 Q3 Loss Widens 71 Phase 1b Clinical Trial 71 Demonstrates Statistically Significant 70 Preclinical Models 70 Sangamo BioSciences Announces 70 Receives NASDAQ 70 Reacquires 70 Successfully Completed 70 Lowers Risk 70 Modulates 70 Treatment Reduces 70 IND Application 70 Files Patent Application 70 Data Suggest 70 Improve Survival 70 Anticancer Drug 70 Osteoporosis Drug 70 Study Validates 70 Commence Phase 70 Protease Inhibitor 70 II Clinical Trial 70 Study Sheds Light 70 Controlled Study 70 Gets FDA Clearance 70 Patents Covering 70 Gene Mutation 70 Oral Laquinimod 70 Previously Treated 70 Drug Combo 70 Develops Novel 70 Single Dose 70 Oral Fingolimod 70 NASDAQ MIPI 70 Board Authorizes 70 Receives Favorable 70 Inflammatory Disease 70 Phase 2a Clinical Trial 70 Genes Identified 70 Clinical Trial Evaluating 70 Levels Linked 70 Arthritis Drug 70 Metabolic Disease 70 Adjuvant Treatment 70 Inhibits 70 Help Predict 70 Dose Ranging Study 70 Disease Modifying 70 Shown Effective 70 Demonstrate Significant 70 Results Confirm 70 estrogen receptor beta agonist 70 Telik Announces 70 Initiates Clinical Trials 70 Files Investigational 70 Effectively Treats 70 Confirms Efficacy 70 Patent Issued 70 First Patient Dosed 70 Novel Antibiotic 70 Metastatic Melanoma 70 PRN FDA Approves 70 Subtypes 70 Gene Variant 70 Predict Risk 70 Hemodialysis Patients 70 Obtains Exclusive License 70 platform HDL Mimetic 70 Phase Ib Clinical Trial 70 Shows Efficacy 69 Mylan Receives Approval 69 Investigational Drug 69 Novel Mechanism 69 Slows Progression 69 Circulating Tumor Cells 69 Completes Patient Enrolment 69 Novel Treatments 69 Induces 69 BioSante Pharmaceuticals Announces 69 Spectrum Pharmaceuticals Announces 69 Treatment Naïve 69 Introduces Novel 69 siRNA Delivery 69 Significantly Increases 69 Randomized Phase 69 Significantly Reduces 69 Immune Responses 69 Expand Collaboration 69 Prostate Cancer Patients 69 Jumps Higher 69 Novel Inhibitor 69 Receives Positive 69 Announce Licensing Agreement 69 Double Blind Placebo 69 Webcast Presentations 69 JAK Inhibitor 69 Q4 Loss Narrows 69 Demonstrates Ability 69 Patients Receiving 69 Rheumatoid Arthritis Drug 69 Cell Transplants 69 Q2 Loss Widens 69 Bone Metastases 69 Study Identifies 69 Adjunctive Therapy 69 Relapsing Multiple Sclerosis 69 Poster Presentations 69 Initiate Clinical Trial 69 Psoriasis Drug 69 Researchers Uncover 69 Expands Scientific Advisory 69 Q4 Loss Widens 69 Statistically Significant 69 Q3 Loss Narrows 69 Further Validates 69 Phase III Trials 69 Successfully Treated 69 Inflammatory Markers 69 PPD Declares 69 Showed Significant 69 Treatment Shows Promise 69 Newly Identified 69 Study Shows Benefits 69 Receives Complete Response 69 Hypertensive Patients 69 Dose Escalation 69 First Patient Treated 69 Orally Active 69 Awarded Patent 69 Genes Involved 69 Aurora Kinase 69 Diagnostic Tests 69 Antisense Drug 69 Clinical Outcome 69 Files Shelf Registration Statement 69 Recombinant Protein 69 Reduces Pain 69 Demonstrates Sustained 69 Discontinues 69 Hematological Malignancies 69 Clinical Study Shows 69 Blood Pressure Drug 69 Tumor Growth 69 Appears Safe 69 Patients Treated 69 CD# CEA 68 Exercises Option 68 Dose Ranging 68 Inc Therapeutic Competitors 68 VIVUS Announces 68 Announces Termination 68 Helps Identify 68 Launches Generic Version 68 Advanced Prostate Cancer 68 Randomized Trials 68 MKC# MT 68 Patients Suffering 68 Develop Innovative 68 Vaccine Protects Against 68 Phase III Pivotal 68 Being Studied 68 Extends Collaboration 68 Sinks Lower 68 Breast Cancer Recurrence 68 Virus Linked 68 Stem Cell Treatment 68 Therapeutic Competitors companiesandmarkets.com adEgemonye 68 Inflammatory Arthritis 68 Hsp# Inhibitor 68 Preterm Labor 68 Treated Patients 68 Drug Prevents 68 Hormone Receptor Positive 68 Submits Application 68 Scientists Uncover 68 Kinase Inhibitors 68 Successful Completion 68 Receptor Agonist 68 Phase 2b Study 68 Poniard Pharmaceuticals Announces 68 Holds Promise 68 Vaccine Candidate 68 Guidelines Issued 68 Severe Sepsis 68 Pivotal Trials 68 Patients Enrolled 68 Well Tolerated 68 Treating Chronic 68 Pharma Merck Serono 68 Study Confirms 68 Chemotherapeutic Agents 68 Humanized Anti 68 Taro Receives 68 Completes Initial 68 AVI BioPharma Announces 68 Patient Treated 68 Hyperlipidemia 68 Hormone Refractory Prostate Cancer 68 Protein Linked 68 HER2 Positive 68 Refractory Hodgkin Lymphoma 68 Anticancer Activity 68 Genes Predict 68 Regains Full 68 Announces Favorable 68 Sapacitabine 68 Topline Results 68 Identifies Key 68 Announces Cancellation 68 Provides Updates 68 Beneficial Effects 68 Infected Patients 68 Significantly Improved 68 AnaSpec Introduces 68 Study Shows Promise 68 Osteoporosis Treatment 68 Schizophrenia Drug 68 Polymerase Inhibitor 68 Lung Cancer Trial 68 FDA Approves 68 Adjuvant Chemotherapy 68 Secondary Hyperparathyroidism 68 Signs Option Agreement 68 Correlation Between 68 Submits Supplemental 68 Therapeutic Vaccine 68 Suppresses 68 Updates Guidance 68 Exclusive License 68 Transplant Patients 68 Multiple Myeloma Patients 68 Sirolimus Eluting Stent 68 R MSCRAMM 68 PDL BioPharma Announces 68 Receives Notification 68 Sign License Agreement 68 Novel Method 68 Flamel Technologies Announces 68 Randomized Double Blind 68 Announces Licensing Agreement 68 Announces License Agreement 68 Receives Conditional 68 Dendritic Cells 68 NDA Submission 68 Asthma Treatment 68 Pharmacokinetic Study 68 Fungal Infections 68 Announce Receipt 68 Telik logo TELINTRA 68 Proves Successful 68 Nasdaq XTLB 68 Shows Statistically Significant 68 Antidepressants Linked 68 Successfully Treats 68 Univest Corporation Declares 68 Clinical Trial Data 67 Novel Compounds 67 DNA Methylation 67 Investigational Agent 67 Q1 Loss Narrows 67 Hematology Molecular Pathology 67 HDAC Inhibitor 67 Acquires Exclusive 67 Improved Survival 67 Proven Effective 67 Cervical Dysplasia 67 Sign Licensing Agreement 67 Key Milestones 67 Q1 Loss Widens 67 Antiviral Drugs 67 Therapeutic Potential 67 Disease Progression 67 FDA Approves Drug 67 Obtains License 67 Achieves Unprecedented 67 Autoimmune Diseases 67 Study Proves 67 Novel Antibody 67 Combo Therapy 67 Survival Benefit 67 Factor Receptor 67 Provides Guidance 67 Updates Status 67 Trial Halted 67 Relapsed Refractory 67 Parathyroid Hormone 67 Provides Clarification 67 Receives Notice 67 MBRX 67 Commercialize Novel 67 Adenoma 67 Autoimmune Disease 67 Insulin Resistance 67 Transdermal Patch 67 Alnylam Nasdaq ALNY 67 Critically Ill Patients 67 Genes Associated 67 Receptor Antagonist 67 Commences Phase III 67 Xcytrin R 67 R lenalidomide 67 Teva Provides Update 67 Randomized Controlled 67 Could Revolutionize 67 Diabetic Foot Ulcer 67 Solid Tumor 67 Personalized Immunotherapy 67 Lupus Nephritis 67 Vascular Inflammation 67 Protein Involved 67 Universal Flu Vaccine 67 Mimetics 67 Successfully Completes 67 Study Examines 67 Monotherapy 67 Receives Funding 67 Kidney Transplant Recipients 67 Miraculins Announces 67 Clinical Evaluation 67 Protein Biomarkers 67 Nasdaq ZGEN 67 Announces Effective Date 67 Host Fourth Quarter 67 Crowflight Announces 67 Reduces Mortality 67 Regains NASDAQ 67 Voluntarily Withdraw 67 Telaprevir VX 67 Subsidiary Enters 67 Closes Financing 67 Seasonal Influenza Vaccine 67 Renal Cell Carcinoma 67 Elderly Patients 67 Immune Cells 67 Chronic Hepatitis C 67 Vicriviroc 67 Respiratory Virus 67 Pharmaceuticals Initiates 67 Hematological Cancers 67 Help Detect 67 Breast Cancer Cells 67 Second Pivotal Phase 67 Vascular Disrupting Agent 67 Inc. NASDAQ SIRT 67 Brentuximab Vedotin SGN 67 Hepatitis C Treatment 67 Romidepsin 67 Renal Cancer 67 Drug Resistant 67 Prostate Cancer Treatment 67 Cholesterol Drug 67 Secures Financing 67 Vaccine Shows Promise 67 Ovarian Cancer Patients 67 Predict Response 67 Subgroup Analysis 67 Chronic Myeloid Leukemia 67 Phase III Clinical Trials 67 Desvenlafaxine Succinate 67 Receives CE Marking 67 Investigational Oral 67 Immune Cell 67 Announce Completion 67 Study Evaluates 67 Statin Therapy 67 microRNA Therapeutics 67 non nucleoside inhibitor 67 Genetic Markers 66 Genentech sanofi aventis 66 Provides Detailed 66 Antiangiogenic 66 Treatment Naive Patients 66 Lung Cancer Survival 66 Amend Merger Agreement 66 Inc. Nasdaq IMGN 66 Nuvelo Announces 66 Anti Angiogenic 66 BiTE Antibody 66 Finalizes Purchase 66 Brain Atrophy 66 Begin Clinical Trials 66 Receives Accreditation 66 Anticancer Agent 66 Sleep Disturbances 66 Therapeutic Vaccines 66 Mutually Agree 66 Less Invasive 66 Announces Commencement 66 Cutaneous T 66 Taglich Brothers Initiates Coverage 66 Anti Angiogenesis 66 Often Misdiagnosed 66 Summarizes 66 Nasdaq Deficiency Notice 66 Abstract Accepted 66 Randomized Double blind 66 Announces Consummation 66 Chemotherapy Improves 66 Leukemia Cells 66 Aptamer 66 agonistic human 66 Relapsed Multiple Myeloma 66 Strengthens Balance Sheet 66 MCSP respectively 66 Amends Agreement 66 Announces Tentative Approval 66 Prove Effective 66 NPS Pharmaceuticals Announces 66 Antiviral Activity 66 Neoadjuvant Chemotherapy 66 Announces Underwriters Exercise 66 Ozarelix 66 Previously Untreated 66 Liver Toxicity 66 Guidelines Recommend 66 Skymark Research Initiates Independent 66 Cocaine Addiction 66 Muscle Wasting 66 ATRA IV 66 Advanced Ovarian Cancer 66 Endothelial Cells 66 Pivotal Trial 66 Begins Shipment 66 Re Affirms 66 Announces Resumption 66 Newly Diagnosed Multiple Myeloma 66 Reports Receipt 66 Preclinical Testing 66 Localized Prostate Cancer 66 Successfully Concludes 66 Postdoctoral Position 66 Anti CD# Antibody 66 Kidney Function 66 Is Well Tolerated 66 Potent Antiviral Activity 66 Fast Track Status 66 MEK Inhibitor 66 Mg Usa 66 Preclinical Evaluation 66 Metastatic Renal Cell Carcinoma 66 Randomized Clinical Trial 66 Successfully Completes Tender Offer 66 Patients Undergoing 66 Strengthens Leadership 66 Therapy Improves 66 Submits Investigational 66 Patient Accrual 66 Provides Clues 66 Reconfirms 66 Nasdaq EPCT 66 Cognitive Problems 66 TriCo Bancshares Announces 66 Bradmer Pharmaceuticals 66 Metastatic Prostate Cancer 66 Closes Previously Announced 66 CNS Disorders 66 Long Term Efficacy 66 Consummates 66 initiated Phase Ib 66 Commercialize 66 Intravenous Formulation 66 Restructures Debt 66 Derma Sciences Announces 66 Renal Cell Cancer 66 Myelodysplastic Syndromes 66 Directors Authorizes 66 Anticancer Compound 66 Novel Vaccine 66 Early Diagnosis 66 Confirmatory Phase 66 Dose Finding 66 Pending Acquisition 66 Malignant Melanoma 66 Raser Technologies Announces 66 Pivotal Clinical Trial 66 product platforms AZX# 66 Rotavirus Vaccine 66 Nanophase Announces 66 Smooth Muscle 66 Corp. AMEX CVM 66 Significantly Expands 66 Extends Tender Offer 66 ARRY # 66 Gene Variation 66 Treatment Experienced 66 Smallpox Vaccine 66 Fracture Risk 66 Breast Tumors 66 Completes Private Placement 66 Preclinical Studies 66 Plaque Psoriasis 66 Pre Cancerous 66 Non Invasive Treatment 66 Completes Financing 66 Announces Signing 66 Resistant Hypertension 66 Host Webcast 66 Postmenopausal Women 66 Therapeutic Antibodies 66 Vitro Activity 66 Anthracycline 66 Inhaled Corticosteroids 66 Immunotherapeutic 66 Files Shelf Registration 66 Myeloma Patients 66 Brain Cells 66 Malaria Vaccine 66 Achieves Significant 66 Completes Tender Offer 66 Castration Resistant Prostate Cancer 66 Fiscal Quarter Results 66 Patient Enrolment 66 Recombinant Human 66 Synthetic Peptide 66 Significantly Improve 66 Receives Unsolicited 65 Meta Analysis 65 Progenitor Cells 65 Ebola Vaccine 65 Autologous Stem Cell Transplantation 65 Crofelemer budesonide foam 65 Vaccine Adjuvants 65 Viral Load 65 Announces Additions 65 Invites Investors 65 Issued Patent 65 Milestone Achieved 65 TRIOLEX ™ 65 Knee Osteoarthritis 65 Colaris Colaris AP 65 Generic Version 65 Sustained Reduction 65 Breast Cancer Treatment 65 Enrolling Patients 65 Finalizes Acquisition 65 Nasdaq PGNX 65 Companion Diagnostic 65 Commence Trading 65 Terminate Merger Agreement 65 Prognostic Value 65 Inc. www.micromet inc.com 65 Vasogen Announces 65 Files Provisional 65 visit http:/www.mannkindcorp.com 65 Randomized Phase II 65 Receives SFDA Approval 65 TELINTRA R 65 Nasdaq MNKD focuses 65 Cognitive Impairment 65 Genetic Tests 65 Cardiovascular Outcomes 65 Limb Ischemia 65 Initiates Voluntary Recall 65 Gene Mutation Linked 65 Tumor Cells 65 Inhaled Nitric Oxide 65 Could Detect 65 Potentially Fatal 65 Therapeutic Targets 65 Multicenter Randomized 65 Adjuvant Therapy 65 Signs Agreements 65 Carboplatin Paclitaxel 65 Enters Into Collaboration 65 Commercializes 65 Hepatocellular 65 Announce Commencement 65 Resubmits 65 Underscores Importance 65 Clostridium difficile Infection 65 Inflammatory Diseases 65 Successfully Complete 65 Diffuse Large B 65 Underwriters Exercise 65 Genetic Variation 65 Rheumatoid Arthritis Patients 65 Hematologic Malignancies 65 Coverage Initiated 65 Systemic Sclerosis 65 Pregnancy Linked 65 Detect Cancer 65 Enzo Biochem Reports 65 Completes Previously Announced 65 Blood Thinner 65 Announces Dismissal 65 Closes Sale 65 Generic Versions 65 Closes Second Tranche 65 Inc. NASDAQ QLTI 65 Develop Next Generation 65 Confirms Receipt 65 Receives Conditional Approval 65 Multicenter Phase 65 Neurodegenerative Disease 65 Inhaled Liposomal Ciprofloxacin 65 Cancer Cachexia 65 Settles Litigation 65 OTC BB PVCT 65 Malignant Glioma 65 Shareholders Approve Acquisition 65 DOR BioPharma Announces 65 Welcomes Analyst Initiation 65 Hepatic Encephalopathy 65 ANADIGICS Announces 65 Preclinical Efficacy 65 Novel Protein 65 Vertebral Fractures 65 IG HCR ;) CO 65 Being Evaluated 65 Q4 Profit Soars 65 Jointly Announce 65 Avian Flu Vaccine 65 Restructures Operations 65 Anti Inflammatory 65 Bullish Average Crossover 65 Clarifies Status 65 Interferon Gamma 65 Diabetic Nephropathy 65 Namenda Memantine HCl 65 Novel Compound 65 Proteasome 65 Medicure Announces 65 Receives Regulatory 65 Inc SPPI 65 Commonly Used 65 Tezampanel 65 Molecular Mechanism 65 Closes Acquisition Of 65 Nasdaq HALO 65 Liver Tumors 65 Cardiac Function 65 5q MDS 65 Advanced Pancreatic Cancer 65 Receives Favorable Ruling 65 Heart Failure Patients 65 Announces Receipt 65 Concludes Acquisition 65 Milestone Payments 65 Secures Additional 65 Closes Acquisition 65 Regeneron Pharma 65 Receives Clearance 65 Emphasizes Importance 65 Plays Role 65 Insights Into 65 J Clin 65 FOLOTYN ® 65 STERIS Corporation Announces 65 Clinically Significant 65 Milestone Payment From 65 Small Molecule Drug 65 Significant Increase 65 Announces Formation 65 Blood Vessel 65 Announces Upcoming 65 Small Molecules 65 evaluating mipomersen 65 lead molecular radiotherapeutic 65 Neural Stem Cells 65 candidates Azedra 65 Transdermal Delivery 65 Histone Deacetylase 65 Nasdaq MNKD focused 65 #:#-#,# CrossRef Medline [002] 65 Unresectable 65 Findings Reveal 65 PEGylated Fab fragment 65 FDA Panel Recommends 65 Left Ventricular Hypertrophy 65 Topical Treatment 65 CYT# potent vascular disrupting 65 Updates Shareholders 65 Aeolus Pharmaceuticals Announces 65 Anemia Drug 65 TNF Blockers 65 Pediatric Patients 65 Transcept Pharmaceuticals 65 Protein Synthesis 65 Receives Positive Opinion 65 Enters Into License Agreement 65 Cell Lymphoma 65 Osteoarthritis Patients 65 Settle Patent Litigation 65 Receives Commitment 65 Line Metastatic Colorectal 65 FY# Loss Widens 65 NASDAQ ENMD 65 Early Relapsing Multiple 65 Naive Patients 65 UGNE 65 Inhaled Insulin 65 Clinical Validation 65 SulphCo Announces 65 Newly Diagnosed 65 Enzyme Replacement Therapy 65 Virus Infection 65 Phase 2a Study 65 telomerase therapeutic 65 Voluntarily Withdraws 65 Closes Merger 65 Immunomodulatory 65 Q2 Profit Surges 65 Breast Cancer Metastasis 65 Plicera TM 64 Randomized Study 64 Node Positive 64 Monoclonal 64 Completes Merger With 64 Sustained Efficacy 64 Issues Guidance 64 Recommends Approval 64 Unveils Revolutionary 64 Enlarged Prostate 64 Significantly Reduced 64 Epilepsy Drugs 64 Plus Ribavirin 64 Breast Cancers 64 TRACON Pharmaceuticals 64 Combination Clinical Trial 64 Clinical Efficacy 64 Previously Announced 64 Treat Anemia 64 Nanoemulsion 64 Bearish Speculation 64 Tyrosine Kinase Inhibitors 64 Researchers Develop 64 Multiple Sclerosis Rheumatoid Arthritis 64 Neural Stem Cell 64 Atypical Hemolytic Uremic Syndrome 64 Ischemic Stroke 64 WorldHeart Announces 64 SIX RO ROG 64 Metastatic Colorectal Cancer 64 Tumor Necrosis Factor 64 dependent kinase inhibitor 64 Underwritten Public 64 Gastrointestinal Disorders 64 See CLINICAL PHARMACOLOGY 64 Human Neural Stem 64 Cardiovascular Disease Risk 64 Recurrent Breast Cancer 64 Stent Restenosis 64 Molecular Diagnostic 64 Mln Common 64 Announce Definitive Agreement 64 Benign Prostatic Hyperplasia 64 Q1 Profit Surges 64 Viral Infections 64 Announce Early Termination 64 Imaging Techniques 64 Emerging Therapies 64 Receives Stockholder Approval 64 Completes Merger 64 Clinical Trials Update 64 lintuzumab SGN 64 developing adecatumumab 64 Nasdaq IMGN 64 Enters Into Definitive 64 Non Invasive 64 Gentium Announces 64 Paclitaxel Carboplatin 64 Results Indicate 64 Anthrax Toxin 64 Renal Impairment 64 Transplant Patient 64 Celebrates Successful 64 Controlled Trial 64 Announces Completion 64 Oral Presentations 64 Helps Detect 64 Complicated Skin 64 Antibiotic Treatment 64 Chronic Hepatitis B 64 Imaging Technique 64 Reveals Significant 64 Lowers Guidance 64 Impairs 64 Chronic Lymphocytic Leukemia CLL 64 Diagnostic Criteria 64 BiTE antibodies targeting 64 Begins Clinical Trial 64 Partial Onset Seizures 64 Spins Out 64 Complete Merger 64 Brain Tumors 64 Endometrial Cancer 64 Projected Release Date 64 Provides Updated 64 please visit http:/www.vandapharma.com 64 Earnings Postmortem 64 Targeted Therapies 64 EntreMed Presents 64 Crit Rev 64 Metabolic Disorder 64 triggers apoptosis programmed 64 Could Predict 64 Lanthanum Carbonate 64 Prodrug 64 Attains 64 Announces Granting 64 TB Vaccine 64 Colorectal Adenomas 64 Nasdaq CTIC 64 Advanced Renal Cell 64 Hospital Acquired Pneumonia 64 PEGylated docetaxel 64 Dry Powder Inhalers 64 Protein Biomarker 64 Aztreonam Lysine 64 Maven Semantic 64 Guides Inline 64 Advanced Colorectal Cancer 64 Refractory Angina 64 Tumor Targeted 64 Male Contraceptive 64 hyaluronidase enzyme 64 Announces Profitable 64 PHRM 64 Tuberculosis Vaccine 64 Expands Portfolio 64 Cholesterol Drugs 64 Geokinetics Announces 64 Licenses Patents 64 Signaling Pathways 64 ORLive Presents 64 Kidney Transplants 64 Multiple Ascending Dose 64 Completes Successful 64 Minimally Invasive Treatment 64 FDA Approves Novel 64 #:#-#,# CrossRef Medline [001] 64 Million Milestone Payment 64 Receives Approvals 64 CRWESelect CRWESelect.com Highlights 64 Announces Filing